The paradoxical behavior of oocyte maturity in advanced age: MII loss and GV gain

Norbert Gleicher's lecture addresses why the familiar logic of scoring oocyte maturity stops working in women of advanced reproductive age and what this changes in IVF strategy. In routine practice the embryologist relies on the share of mature metaphase II (MII) oocytes as the main marker of retrieval quality, while immature germinal vesicle (GV) stage cells are traditionally treated as ballast. The author shows that with age this hierarchy becomes far less clear-cut.

To explain the paradox, the lecture first revisits the basic physiology of oocyte maturation. Nuclear maturation — the transition from prophase I through resumption of meiosis to metaphase II — is normally synchronised with cytoplasmic maturation, which equips the cell with the stores of mRNA, mitochondria and proteins needed for fertilisation and the first divisions. It is the coordination of these two processes, not merely the formal nuclear stage, that determines oocyte competence.

The central thesis is the paradoxical behaviour of oocyte maturity in advanced age. As the ovary ages, the effectiveness of cells retrieved already mature at the MII stage declines: aneuploidy becomes more frequent, spindle abnormalities appear more often, and nuclear and cytoplasmic maturation fall out of step. At the same time, oocytes aspirated immature at the GV stage, when matured in culture, show in a number of observations a relatively rising contribution to the final outcome.

Gleicher discusses the physiological mechanisms of this phenomenon as working hypotheses rather than proven causal links. He considers that some GV oocytes may have been held back in development by features of the follicular environment and stimulation rather than by true immaturity, and that their subsequent in vitro maturation sometimes yields cells with better preserved genomic and cytoplasmic integrity than oocytes that have aged already in the MII state.

The speaker also stresses the limits of interpretation. The point is a shift in relative effectiveness, not a call to abandon MII oocytes; the conclusions concern above all the cohort of older, low-prognosis women, where the absolute number of oocytes is small and the value of each cell is high. The patterns are discussed at the level of a concept and observed trends, without extrapolating single figures to the whole population.